☆ 4.5 Letter

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases

BONE MARROW TRANSPLANTATION (2023)

Related references

Note: Only part of the references are listed.
Article Immunology

Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality

Jennifer Kertes et al.

Summary: During the fifth wave of Omikron-dominated COVID-19, intramuscular AZD7442 treatment among immunocompromised individuals was associated with a lower risk of SARS-CoV-2 infection and severe disease.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection
Article Biochemistry & Molecular Biology

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Wanwisa Dejnirattisai et al.

Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.

CELL (2022)

Add to Collection
Article Oncology

Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis

Thomas Hueso et al.

Summary: Patients with hematological malignancy and COVID-19 have a high mortality rate. COVID-19 convalescent plasma (CCP) therapy shows promise in transferring neutralizing antibodies to enhance the immune response. In patients with B-cell lymphoid disease who have received anti-CD20 therapy, CCP treatment is associated with a lower mortality rate.

LEUKEMIA (2022)

Add to Collection
Letter Oncology

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

Robert Stuver et al.

CANCER CELL (2022)

Add to Collection
Article Hematology

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

Maggie Li et al.

Summary: The COVID-19 convalescent plasma (CCP) with high antibody levels effectively reduces hospitalization for immunocompetent outpatient. The study found that CCP can effectively neutralize the three variants.

BLOOD ADVANCES (2022)

Add to Collection
Letter Hematology

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Ola Blennow et al.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection
Review Hematology

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Abi Vijenthira et al.

BLOOD (2020)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.